List of Excipients in API nilotinib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing nilotinib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | TASIGNA | nilotinib | 0078-0526 | CROSPOVIDONE | |
| Novartis Pharmaceuticals Corporation | TASIGNA | nilotinib | 0078-0526 | FERRIC OXIDE RED | |
| Novartis Pharmaceuticals Corporation | TASIGNA | nilotinib | 0078-0526 | FERRIC OXIDE YELLOW | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for nilotinib
Excipient focus: CELLULOSE, MICROCRYSTALLINE
nilotinib drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Azurity Pharmaceuticals Inc | nilotinib | 24338-154 |
| >Company | >Ingredient | >NDC |
nilotinib drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | nilotinib | 0078-0526 |
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
nilotinib drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Azurity Pharmaceuticals Inc | nilotinib | 24338-154 |
| >Company | >Ingredient | >NDC |
nilotinib drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | nilotinib | 0078-0526 |
| >Company | >Ingredient | >NDC |
Excipient focus: CROSPOVIDONE
nilotinib drug variants containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | nilotinib | 0078-0526 |
| >Company | >Ingredient | >NDC |
nilotinib drug variants not containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Azurity Pharmaceuticals Inc | nilotinib | 24338-154 |
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
nilotinib drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | nilotinib | 0078-0526 |
| >Company | >Ingredient | >NDC |
nilotinib drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Azurity Pharmaceuticals Inc | nilotinib | 24338-154 |
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
nilotinib drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | nilotinib | 0078-0526 |
| >Company | >Ingredient | >NDC |
nilotinib drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Azurity Pharmaceuticals Inc | nilotinib | 24338-154 |
| >Company | >Ingredient | >NDC |
Excipient focus: GELATIN
nilotinib drug variants containing GELATIN
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | nilotinib | 0078-0526 |
| >Company | >Ingredient | >NDC |
nilotinib drug variants not containing GELATIN
| Company | Ingredient | NDC |
|---|---|---|
| Azurity Pharmaceuticals Inc | nilotinib | 24338-154 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE ACETATE SUCCINATE 12070923
nilotinib drug variants containing HYPROMELLOSE ACETATE SUCCINATE 12070923
| Company | Ingredient | NDC |
|---|---|---|
| Azurity Pharmaceuticals Inc | nilotinib | 24338-154 |
| >Company | >Ingredient | >NDC |
nilotinib drug variants not containing HYPROMELLOSE ACETATE SUCCINATE 12070923
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | nilotinib | 0078-0526 |
| >Company | >Ingredient | >NDC |
Excipient focus: LACTOSE MONOHYDRATE
nilotinib drug variants containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | nilotinib | 0078-0526 |
| >Company | >Ingredient | >NDC |
nilotinib drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Azurity Pharmaceuticals Inc | nilotinib | 24338-154 |
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
nilotinib drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | nilotinib | 0078-0526 |
| Azurity Pharmaceuticals Inc | nilotinib | 24338-154 |
| >Company | >Ingredient | >NDC |
nilotinib drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLOXAMER 188
nilotinib drug variants containing POLOXAMER 188
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | nilotinib | 0078-0526 |
| >Company | >Ingredient | >NDC |
nilotinib drug variants not containing POLOXAMER 188
| Company | Ingredient | NDC |
|---|---|---|
| Azurity Pharmaceuticals Inc | nilotinib | 24338-154 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 3350
nilotinib drug variants containing POLYETHYLENE GLYCOL 3350
| Company | Ingredient | NDC |
|---|---|---|
| Azurity Pharmaceuticals Inc | nilotinib | 24338-154 |
| >Company | >Ingredient | >NDC |
nilotinib drug variants not containing POLYETHYLENE GLYCOL 3350
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | nilotinib | 0078-0526 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
nilotinib drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Azurity Pharmaceuticals Inc | nilotinib | 24338-154 |
| >Company | >Ingredient | >NDC |
nilotinib drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | nilotinib | 0078-0526 |
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
nilotinib drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | nilotinib | 0078-0526 |
| Azurity Pharmaceuticals Inc | nilotinib | 24338-154 |
| >Company | >Ingredient | >NDC |
nilotinib drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
nilotinib drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | nilotinib | 0078-0526 |
| Azurity Pharmaceuticals Inc | nilotinib | 24338-154 |
| >Company | >Ingredient | >NDC |
nilotinib drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
